Table 1.
Variable | Reseveratrol (n = 26) | Placebo (n = 26) |
---|---|---|
Gender, F(%) | 10 (38%) | 11 (42%) |
Age, mean ± SD | 34.73 ± 7.03 | 33.08 ± 5.48 |
Duration of illness, y, mean ± SD | 11.46 ± 6.43 | 10.65 ± 5.20 |
Schizophrenia subtype | ||
Paranoid(%) | 16 (61%) | 17 (69%) |
Residual(%) | 4 (15%) | 5 (19%) |
Undifferentiated(%) | 6 (23%) | 5 (19%) |
Marital status | Single: 16 (61%) | Single: 18 (69%) |
Married: 7 (27%), | Married: 5 (19%), | |
Divorced: 3 (11%) | Divorced: 3 (11%) | |
Level of education | Less than high school diploma: 19 (73%), diploma: 4 (15%), illiterate: 3 (11%) |
Less than high school diploma: 17 (69%), diploma: 7 (27%), illiterate 2 (7%) |
Smoking | 22 (84%) | 23 (88%) |
Baseline HDRS score, mean ± SD | 9.84 ± 1.97 | 10.15 ± 1.97 |
Baseline ESRS, mean ± SD | 0.77 ± 0.99 | 0.38 ± 0.70 |
Baseline PANSS | ||
Total score | 70.08 ± 5.11 | 70.27 ± 4.21 |
Negative symptoms | 17.69 ± 2.53 | 18.04 ± 1.75 |
Positive symptoms | 20.58 ± 1.90 | 20.31 ± 2.17 |
General psychopathology | 31.81 ± 2.40 | 31.92 ± 1.74 |
Abbreviations: ESRS, extrapyramidal symptom rating scale; F, female; HDRS, Hamilton Depression Rating Scale; PANSS, positive and negative syndrome scale.